From Dose Reduction to Contrast Maximization: Can Deep Learning Amplify the Impact of Contrast Media on Brain Magnetic Resonance Image Quality? A Reader Study.
Journal
Investigative radiology
ISSN: 1536-0210
Titre abrégé: Invest Radiol
Pays: United States
ID NLM: 0045377
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
22
4
2022
medline:
12
7
2022
entrez:
21
4
2022
Statut:
ppublish
Résumé
The aim of this study was to evaluate a deep learning method designed to increase the contrast-to-noise ratio in contrast-enhanced gradient echo T1-weighted brain magnetic resonance imaging (MRI) acquisitions. The processed images are quantitatively evaluated in terms of lesion detection performance. A total of 250 multiparametric brain MRIs, acquired between November 2019 and March 2021 at Gustave Roussy Cancer Campus (Villejuif, France), were considered for inclusion in this retrospective monocentric study. Independent training (107 cases; age, 55 ± 14 years; 58 women) and test (79 cases; age, 59 ± 14 years; 41 women) samples were defined. Patients had glioma, brain metastasis, meningioma, or no enhancing lesion. Gradient echo and turbo spin echo with variable flip angles postcontrast T1 sequences were acquired in all cases. For the cases that formed the training sample, "low-dose" postcontrast gradient echo T1 images using 0.025 mmol/kg injections of contrast agent were also acquired. A deep neural network was trained to synthetically enhance the low-dose T1 acquisitions, taking standard-dose T1 MRI as reference. Once trained, the contrast enhancement network was used to process the test gradient echo T1 images. A read was then performed by 2 experienced neuroradiologists to evaluate the original and processed T1 MRI sequences in terms of contrast enhancement and lesion detection performance, taking the turbo spin echo sequences as reference. The processed images were superior to the original gradient echo and reference turbo spin echo T1 sequences in terms of contrast-to-noise ratio (44.5 vs 9.1 and 16.8; P < 0.001), lesion-to-brain ratio (1.66 vs 1.31 and 1.44; P < 0.001), and contrast enhancement percentage (112.4% vs 85.6% and 92.2%; P < 0.001) for cases with enhancing lesions. The overall image quality of processed T1 was preferred by both readers (graded 3.4/4 on average vs 2.7/4; P < 0.001). Finally, the proposed processing improved the average sensitivity of gradient echo T1 MRI from 88% to 96% for lesions larger than 10 mm ( P = 0.008), whereas no difference was found in terms of the false detection rate (0.02 per case in both cases; P > 0.99). The same effect was observed when considering all lesions larger than 5 mm: sensitivity increased from 70% to 85% ( P < 0.001), whereas false detection rates remained similar (0.04 vs 0.06 per case; P = 0.48). With all lesions included regardless of their size, sensitivities were 59% and 75% for original and processed T1 images, respectively ( P < 0.001), and the corresponding false detection rates were 0.05 and 0.14 per case, respectively ( P = 0.06). The proposed deep learning method successfully amplified the beneficial effects of contrast agent injection on gradient echo T1 image quality, contrast level, and lesion detection performance. In particular, the sensitivity of the MRI sequence was improved by up to 16%, whereas the false detection rate remained similar.
Identifiants
pubmed: 35446300
doi: 10.1097/RLI.0000000000000867
pii: 00004424-202208000-00005
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
527-535Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: Research study funded by Guerbet. Among its portfolio of solutions for medical imaging, Guerbet commercializes Dotarem (gadoterate meglumine), a gadolinium-based contrast agent.
Références
Weller M, Wick W, Aldape K, et al. Glioma. Nat Rev Dis Primers . 2015;1:15017.
Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers . 2019;5:5.
Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol . 2019;20:1493–1505.
Bjørnerud A, Vatnehol SAS, Larsson C, et al. Signal enhancement of the dentate nucleus at unenhanced MR imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent gadobutrol: an observational study. Radiology . 2017;285:434–444.
Ramalho J, Semelka RC, Ramalho M, et al. Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol . 2016;37:1192–1198.
Fraum TJ, Ludwig DR, Bashir MR, et al. Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging . 2017;46:338–353.
European Medicines Agency. EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans. 2017. Document Reference: EMA/625317/2017. Available at: https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents_en.pdf . Accessed March 7, 2022.
United States Food and Drug Administration. FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings [press release]. 2018. Document Reference: 109825. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body . Accessed February 25, 2021.
Yuh WT, Engelken JD, Muhonen MG, et al. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol . 1992;13:335–345.
Akeson P, Larsson EM, Kristoffersen DT, et al. Brain metastases—comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol . 1995;36:300–306.
Essig M, Anzalone N, Combs SE, et al. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol . 2012;33:803–817.
Kim ES, Chang JH, Choi HS, et al. Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine. AJNR Am J Neuroradiol . 2010;31:1055–1058.
Bendszus M, Roberts D, Kolumban B, et al. Dose finding study of gadopiclenol, a new macrocyclic contrast agent, in MRI of central nervous system. Invest Radiol . 2020;55:129–137.
Park J, Kim J, Yoo E, et al. Detection of small metastatic brain tumors: comparison of 3D contrast-enhanced whole-brain black-blood imaging and MP-RAGE imaging. Invest Radiol . 2012;47:136–141.
Majigsuren M, Abe T, Kageji T, et al. Comparison of brain tumor contrast-enhancement on T1-cube and 3D-SPGR images. Magn Reson Med Sci . 2016;15:34–40.
Oh J, Choi SH, Lee E, et al. Application of 3D fast spin-echo T1 black-blood imaging in the diagnosis and prognostic prediction of patients with leptomeningeal carcinomatosis. AJNR Am J Neuroradiol . 2018;39:1453–1459.
Suh CH, Jung SC, Kim KW, et al. The detectability of brain metastases using contrast-enhanced spin-echo or gradient-echo images: a systematic review and meta-analysis. J Neurooncol . 2016;129:363–371.
Kaufmann TJ, Smits M, Boxerman J, et al. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol . 2020;22:757–772.
Bapst B, Amegnizin JL, Vignaud A, et al. Post-contrast 3D T1-weighted TSE MR sequences (SPACE, CUBE, VISTA/BRAINVIEW, isoFSE, 3D MVOX): technical aspects and clinical applications. J Neuroradiol . 2020;47:358–368.
Edelman R, Leloudas N, Pang J, et al. Twofold improved tumor-to-brain contrast using a novel T1 relaxation-enhanced steady-state (T1RESS) MRI technique. Sci Adv . 2020;6:eabd1635.
Higaki T, Nakamura Y, Tatsugami F, et al. Improvement of image quality at CT and MRI using deep learning. Jpn J Radiol . 2019;37:73–80.
Zhu G, Jiang B, Tong L, et al. Applications of deep learning to neuro-imaging techniques. Front Neurol . 2019;10:869.
Jiang D, Dou W, Vosters L, et al. Denoising of 3D magnetic resonance images with multi-channel residual learning of convolutional neural network. Jpn J Radiol . 2018;36:566–574.
Gondara L. Medical image denoising using convolutional denoising autoencoders. 2016 IEEE 16th International Conference on Data Mining Workshops (ICDMW) . 2016;241–246.
Kim KH, Choi SH, Park SH. Improving arterial spin labeling by using deep learning. Radiology . 2018;287:658–666.
Liu F, Jang H, Kijowski R, et al. Deep learning MR imaging-based attenuation correction for PET/MR imaging. Radiology . 2018;286:676–684.
Yoon BC, Saad AF, Rezaii P, et al. Evaluation of thick-slab overlapping MIP images of contrast-enhanced 3D T1-weighted CUBE for detection of intracranial metastases: a pilot study for comparison of lesion detection, interpretation time, and sensitivity with nonoverlapping CUBE MIP, CUBE, and inversion-recovery-prepared fast-spoiled gradient recalled brain volume. AJNR Am J Neuroradiol . 2018;39:1635–1642.
Pasumarthi S, Tamir JI, Christensen S, et al. A generic deep learning model for reduced gadolinium dose in contrast-enhanced brain MRI. Magn Reson Med . 2021;86:1687–1700.
Luo H, Zhang T, Gong NJ, et al. Deep learning-based methods may minimize GBCA dosage in brain MRI. Eur Radiol . 2021;31:6419–6428.
Ammari S, Bône A, Balleyguier C, et al. Can deep learning replace gadolinium in neuro-oncology?: a reader study. Invest Radiol . 2022;57:99–107.
Kleesiek J, Morshuis JN, Isensee F, et al. Can virtual contrast enhancement in brain MRI replace gadolinium?: a feasibility study. Invest Radiol . 2019;54:653–660.
Gong E, Pauly JM, Wintermark M, et al. Deep learning enables reduced gadolinium dose for contrast-enhanced brain MRI. J Magn Reson Imaging . 2018;48:330–340.
Thust SC, Heiland S, Falini A, et al. Glioma imaging in Europe: a survey of 220 centres and recommendations for best clinical practice. Eur Radiol . 2018;28:3306–3317.
Bone A, Ammari S, Lamarque JP, et al. Contrast-enhanced brain MRI synthesis with deep learning: key input modalities and asymptotic performance. Proceedings of the IEEE International Symposium on Biomedical Imaging . 2021;1159–1163.
Milletari F, Navab N, Ahmadi SA. V-Net: fully convolutional neural networks for volumetric medical image segmentation. Proceedings of the Fourth International Conference on 3D Vision . 2016;565–571.
Drozdzal M, Vorontsov E, Chartrand G, et al. The importance of skip connections in biomedical image segmentation. In: Carneiro G, Mateus D, Peter L, et al., eds. Deep Learning and Data Labeling for Medical Applications. DLMIA 2016, LABELS 2016. Lecture Notes in Computer Science vol. 10008. Cham, Switzerland: Springer; 2016:179–187.
Fagerland MW, Lydersen S, Laake P. The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional. BMC Med Res Methodol . 2013;13:91.
Scoccianti S, Detti B, Gadda D, et al. Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist's guide for delineation in everyday practice. Radiother Oncol . 2015;114:230–238.